Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study-Reference-Cited by-同舟云学术

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study

Published:2023-12 Issue: Volume:122 Page:104221
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Parkin Stephen^ORCID,Neale Joanne^ORCID,Strang John

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference53 articles.

1. Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia;Andrada;Australian Journal of General Practice,2022

2. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia;Barnett;Drug and Alcohol Dependence,2021

3. Medication treatment of opioid use disorder;Bell;Biological Psychiatry,2020

4. Buvidal® eu summary of product characteristics (SmPC);Camurus,2021

5. Weekly/Monthly buvidal buprenorphine prolonged release solution for injection. Healthcare professional information booklet;Camurus,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment engagement in comorbid alcohol use disorder and alcohol‐related liver disease: A qualitative exploration of barriers and facilitators with service users;Alcohol, Clinical and Experimental Research;2024-08-27

2. Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients’ Interpersonal Relationships during the First Year of Treatment;Substance Use & Misuse;2024-08-20

3. ‘Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study;International Journal of Drug Policy;2024-07